Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) | RFA CA 19 022

Opportunity Information: Apply for RFA CA 19 022

The National Cancer Institute (NCI), within the National Institutes of Health (NIH) at the Department of Health and Human Services, offered this grant opportunity to push forward practical, high-impact technologies that make cancer-related biospecimens more reliable for research and clinical use. The focus is on the often-overlooked period before a specimen is analyzed, meaning everything that happens during collection, processing, handling, and storage. During these steps, important biological signals (targeted analytes such as DNA, RNA, proteins, metabolites, and other molecular markers) can degrade or change, introducing pre-analytical variation that can distort results. This FOA centers on technologies that reduce those problems by preserving sample integrity, monitoring quality in real time or after the fact, and creating stronger, more standardized ways to verify that a sample is still fit for downstream testing.

This announcement specifically used the R33 funding mechanism, which is generally meant for later-stage exploratory and developmental work where the basic feasibility has already been demonstrated. In other words, applicants were expected to come in with solid preliminary data showing that the core concept works and that the biggest feasibility risks have been addressed. The remaining work should still be significant: further development, optimization, and, most importantly, rigorous validation so that the technology is credible and adoptable by the broader research community. The intent is not just to build clever prototypes, but to produce tools, devices, instruments, or methods that can be trusted, compared across settings, and realistically integrated into workflows used by biobanks, research labs, and clinical environments.

A central theme of the FOA is improving the quality and utility of biological samples used for downstream analyses. That can include technologies that actively protect specimens from degradation (for example, improved stabilization approaches, better collection devices, smarter storage or transport solutions, or methods that minimize handling damage), as well as technologies that interrogate specimen quality (for example, quality assessment/quality control systems, verification criteria, or metrics that indicate whether a sample has been compromised). The FOA also emphasizes performance under diverse conditions, recognizing that real-world biospecimen collection happens across many environments with different resources, time constraints, and infrastructure. Methods that can handle variability in temperature, delays before processing, shipping conditions, or inconsistent handling practices are particularly relevant because they address a major source of irreproducibility in cancer research and inconsistency in clinical testing.

By reducing pre-analytical variation, the funded projects were expected to strengthen multiple areas of cancer science and care. Better biospecimens can improve basic cancer biology studies by ensuring measured molecular changes reflect biology rather than handling artifacts. They can enhance early detection and screening by making low-abundance signals easier to detect and by reducing false negatives or misleading biomarker fluctuations. They can also support clinical diagnosis and treatment decisions by improving the reliability of molecular profiling and other lab-based assessments. Beyond individual patient care and lab studies, improved biospecimen quality matters in epidemiology and population research, where samples collected across sites and time periods need consistent handling to allow valid comparisons. The FOA also highlights the potential to address cancer health disparities, since inconsistent collection conditions and resource limitations can disproportionately affect sample quality in certain settings; robust, field-tolerant technologies can help make data quality more equitable across populations.

This opportunity was part of NCI's broader Innovative Molecular Analysis Technologies (IMAT) Program, which aims to accelerate the creation and adoption of transformative technologies that enable better molecular measurements and analyses in cancer. While IMAT often brings to mind novel assays or molecular detection platforms, this FOA zeroes in on the upstream foundation that those assays depend on: the specimen itself. The underlying message is that even the best analytical methods cannot compensate for poorly preserved or poorly characterized inputs, so investments in biospecimen science technologies can have outsized downstream impact.

Administratively, the FOA was identified as RFA-CA-19-022 under the assistance listing (CFDA) 93.394. It was a discretionary grant program with an award ceiling listed at $300,000, and the expected number of awards was two. The announcement allowed a wide range of applicants, including federal recognized tribal governments and tribal organizations, state and local governments, public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and other entities as described in the eligibility text. The FOA was posted in early January 2019 with an original closing date in late September 2019. It explicitly indicated that clinical trials were not allowed under this funding mechanism, signaling that the supported work should focus on technology development and validation rather than testing interventions through clinical trial designs.

Overall, the grant opportunity targeted a clear bottleneck in cancer research and clinical translation: inconsistent biospecimen quality and the hidden damage caused by pre-analytical factors. It sought projects that are past the initial "can it work" stage and ready for disciplined engineering, refinement, and validation work that demonstrates reliability, robustness, and practical value. The goal was to deliver emerging technologies that the cancer research community can adopt to generate cleaner data, more comparable results across studies and sites, and ultimately faster progress in understanding, detecting, and treating cancer.

• The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on Jan 07, 2019.
• Applicants must submit their applications by Sep 27, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for RFA CA 19 022

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: